Atlas Trials

A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain

Clinical trial NCT06746116 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06746116
Sponsor
AstraZeneca
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Advanced or Recurrent Endometrial Cancer
Start date
2024-12-30
Primary completion
2028-11-30
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.